Deep TMS News - Get The Latest News On BrainsWay's Deep TMS

News & Events

March 11, 2026

BrainsWay Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

BrainsWay Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights Q4 Revenue...

March 4, 2026

Landmark Data Validate BrainsWay’s SWIFT™ Deep TMS, Beginning a New Era in Depression Treatment

BURLINGTON, Mass. and JERUSALEM, March 4, 2026 — BrainsWay Ltd. (NASDAQ & TASE: BWAY) unveiled...

February 17, 2026

BrainsWay Announces Change in ADS-to-Ordinary Share Ratio

Change in ADS ratio aimed at simplifying comparisons to ordinary shares traded on the Tel Aviv Stock...

January 12, 2026

BrainsWay Announces FDA Approval of Neurolief’s Proliv™Rx Neuromodulation System for Major Depressive Disorder (MDD)

BrainsWay’s strategic investment in Neurolief paved the way for the first and only FDA approved at-home...

December 22, 2025

BrainsWay Announces First Coverage Policy for Accelerated Deep TMS™

New Premera Blue Cross policy extends to both adolescent and adult depression patients BURLINGTON, Mass....

November 25, 2025

BrainsWay to Host Virtual Analyst & Investor Day to Discuss the Company’s Growth Strategy and Deep TMS™ Treatment December 1, 2025

BURLINGTON, Mass. and JERUSALEM, Nov. 25, 2025 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ &...

, November 21, 2025

BrainsWay Receives FDA Clearance of Deep TMS™ as Adjunct Therapy for Major Depressive Disorder (MDD) in Adolescents Aged 15 to 21

Deep TMS™ becomes first and only TMS device cleared in treatment of patients ages 15 to 86 suffering...

November 20, 2025

BrainsWay Launches First Clinical Trial of Deep TMS 360™ System for Alcohol Use Disorder

Multicenter, randomized, controlled study will evaluate Company’s next-generation multichannel TMS...

November 1, 2026

BrainsWay Reports Third Quarter 2025 Financial Results and Operational Highlights

Revenue increased 29% to $13.5 million in Q3 2025 as compared with Q3 2024 Operating income totaled...

October 27, 2025

BrainsWay Announces Additional Minority-Stake Investments in Leading U.S. Mental Health Providers

Recent agreements with two additional U.S. mental health providers bring total to four in 2025 Strategy...

October 28, 2025

BrainsWay to Report Third Quarter 2025 Financial Results on November 11, 2025

BURLINGTON, Mass. and JERUSALEM, Oct. 28, 2025 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ &...

September 16, 2025

BrainsWay Receives FDA Clearance for Accelerated Deep TMS Protocol for Non-Invasive Treatment of Major Depressive Disorder (MDD)

Clinical data shows that BrainsWay’s new accelerated stimulation protocol is comparable to standard...

August 21, 2025

BrainsWay Targets Expansion of its Total Addressable Market through a Strategic Investment in Neuromodulation Systems Developer, Neurolief Ltd.

This investment marks BrainsWay’s entrance into the market for mental health therapies that can be...

August 20, 2025

BrainsWay Acquires Minority-Stake in Axis Integrated Mental Health

The Investment is part of BrainsWay’s ongoing strategy to acquire minority positions in leading U.S....

August 13, 2025

BrainsWay Reports Second Quarter 2025 Financial Results and Operational Highlights

Achieved record quarterly revenue of $12.6 million in Q2 2025, an increase of 26% compared to Q2 2024 Operating...

July 31, 2025

BrainsWay Champions TMS Education with Sponsorship of Two Free CME Courses for Mental Health Professionals

BURLINGTON, Mass. and JERUSALEM, Israel, July 30, 2025 (GLOBE NEWSWIRE) — BrainsWay, a global...

July 30, 2025

BrainsWay to Report Second Quarter 2025 Financial Results on August 13, 2025

BrainsWay to Report Second Quarter 2025 Financial Results on August 13, 2025 Download PDF BURLINGTON,...

July 17, 2025

Medscape CME Course: Data-Driven Insights for Incorporating Transcranial Magnetic Stimulation Into Your Practice

Data-Driven Insights for Incorporating Transcranial Magnetic Stimulation Into Your Practice Discover...